TRACON Pharmaceuticals Reports Ongoing Complete Response in Choriocarcinoma Patient Treated With Company's TRC105 in Compassionate Use Phase 2 Clinical Trial Conducted at Dana-Farber Cancer Institute

SAN DIEGO, Sept. 18, 2015 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and...